Friday, July 8, 2016
Cambodia - Sanofi Cambodia Launches New Vaccine Against Japanese Encephalitis (JE)
Sanofi Cambodia, one of the leading pharmaceutical companies in Cambodia, introduced a new vaccine so-called Imojev, a vaccine against JE, to Cambodia’s market with participation of more than 200 healthcare professionals.
Vaccination against JE should occur before exposure to risk. For people living in endemic regions, this should be in early childhood. Imojev can be administered as early as nine months of age. It can also be used in adults in endemic regions or travelers, and has a rapid onset of protection.
On this occasion, Mr. Tomas Gaudry, Vaccine Head of Vietnam and Cambodia, said during the event at the Sokha hotel that “Japanese Encephalitis (JE) has also been identified as a major cause of neurological disabilities. At least 50 percent of children who survive the illness are left with severe consequences, including physical, cognitive, or psychiatric problems which are life-long for most victims. There are an estimated 60,000 clinical cases and 15,000 deaths annually in the Asia regions, which caused by JE.”
Doctor Alain Bouckenooghe Dr Bouckenooghe, Associate VP and Regional Head of Clinical R&D Sanofi Pasteur, Asia Pacific hub, also explained that this illness is not transmitted from human to human but only through a particular species of mosquitos. Symptoms include high-grade fever, nausea, vomiting, altered sensory experiences, convulsions, neck stiffness, muscular rigidity and abnormal movements.
Infants from age 9 months to 60 years old can be vaccinatted against JE. Injections against JE need to be administered by professional doctors.
Head of Sanofi Cambodia, Ms. Minh said, “The new product launched today proves that Sanofi is continuing its commitment to make more quality products available for the country’s healthcare needs. Sanofi also closely collaborates with healthcare professionals to bring better and safer prevention methods to Cambodian people, especially children.”